A Randomized Crossover Pilot Study of Telemedicine Delivered via iPads in Parkinson’s Disease

Table 2

Changes in clinical measures during telemedicine and control periods (median, interquartile range, and value).

	Telemedicine period		Control period		value
	Baseline	6 months	Baseline	6 months
PDQ39 SI	95.45 (26.45–195.425)	94.45 (48.45–193.15)	90.4 (54.375–224.725)	102.1 (64.35–174.675)	0.87
UPDRS part III	22.0 (12.0–25.5)	19.0 (8.5–24.0)	23.0 (9.5–28.0)	22.0 (7.5–26.5)	0.08
BDI	3.5 (0–6.75)	5.5 (0.75–10.75)	6.5 (0.75–9.75)	3.5 (0–8.25)	0.64
UPDRS part I	1.0 (0–2.0)	1.0 (0–2.0)	1.0 (0–2.0)	1.0 (0–2.0)	0.93
UPDRS part II	5.0 (4.0–6.5)	6.0 (3.0–7.5)	6.0 (3.0–8.0)	6.0 (3.5–8.5)	0.89
UPDRS part IV	2.0 (0–3.0)	2.0 (0.5–2.5)	2.0 (0.5–3.0)	2.0 (0.5–2.5)	0.93
Modified Hoehn and Yahr stage	2.0 (2.0–2.0)	2.0 (2.0–2.0)	2.0 (2.0–2.0)	2.0 (1.5–2.0)	0.26